(Total Views: 771)
Posted On: 06/07/2020 5:05:12 PM
Post# of 148908
Proof that Patterson is unblinded: the IVRS number
OK, so blafarm's post includes several pastes from investorshub.
One of those pasted posts identifies something called an "IVRS" number.
The investorshub poster further claims that every clinical trial sample includes a unique patient identifier, known as the "IVRS" number.
IVRS stands for Interactive Voice Response System. Apparently the unique patient identifier got its start as a code word which grants medical care practitioners acces to a particular human clinical trial and or supply system through an automated attendant.
So it looks like the FDA does have a protocol, and that protocol does include unique patient identifier on every blood sample vial.
Which means that Patterson can easily tracky patients through the study.
And when the primary endpoint is mortality, Patterson easily computes the trial primary endpoint, including p-value, as he recognizes that if the samples stop coming in then probably the patient died.
Patterson has sufficient experience that he can compute the severe/critical mortality primary endpoint in his head.
Heck, he probably re-computes the primary trial endpoint p-value every evening just for fun.
Now the only remaining question is whether he is allowed to tell anyone about this.
It is notable that Patterson is the ONLY person who can compute the primary endpoint in realy time because 1) Patterson is the ONLY person who has acces to all patients, and 2) Patterson MAY BE the only person who has access to the CCR5 receptor occupancy assay needed to discriminate between leronlimab and placebo.
OK, so blafarm's post includes several pastes from investorshub.
One of those pasted posts identifies something called an "IVRS" number.
The investorshub poster further claims that every clinical trial sample includes a unique patient identifier, known as the "IVRS" number.
IVRS stands for Interactive Voice Response System. Apparently the unique patient identifier got its start as a code word which grants medical care practitioners acces to a particular human clinical trial and or supply system through an automated attendant.
So it looks like the FDA does have a protocol, and that protocol does include unique patient identifier on every blood sample vial.
Which means that Patterson can easily tracky patients through the study.
And when the primary endpoint is mortality, Patterson easily computes the trial primary endpoint, including p-value, as he recognizes that if the samples stop coming in then probably the patient died.
Patterson has sufficient experience that he can compute the severe/critical mortality primary endpoint in his head.
Heck, he probably re-computes the primary trial endpoint p-value every evening just for fun.
Now the only remaining question is whether he is allowed to tell anyone about this.
It is notable that Patterson is the ONLY person who can compute the primary endpoint in realy time because 1) Patterson is the ONLY person who has acces to all patients, and 2) Patterson MAY BE the only person who has access to the CCR5 receptor occupancy assay needed to discriminate between leronlimab and placebo.
(5)
(0)Scroll down for more posts ▼
